Showing 371-380 of 404 results for "".
- SkinMedica's DiamondGlow Hits Doctor's Officeshttps://modernaesthetics.com/news/skinmedicas-diamondglow-hits-doctors-offices/2472875/llergan’s Skinmedica is rolling out DiamondGlow, a non-invasive dermabrasion technology that exfoliates, extracts, and treats the face, eye area, lips and body. Allergan acquired Envy Medical, Inc and its Silkpeel&nbs
- Alma’s Opus Plasma Debuts in North Americahttps://modernaesthetics.com/news/almas-opus-plasma-debuts-in-north-america/2472871/Alma, Inc. is launching Opus in North America. Opus is a new platform featuring the company's proprietary high-frequency unipolar radio-frequency technology, Opus Plasma. Opus Plasma is the first fractional plasma technology to enter the f
- Revance Enters Exclusive Distribution Deal with Teoxane SA for Dermal Fillershttps://modernaesthetics.com/news/revance-enters-exclusive-distribution-deal-with-teoxane-sa-for-dermal-fillers/2472863/With the signing of a new distribution agreement, Revance Therapeutics, Inc. is now the exclusive US commercialization partner of Teoxane SA for its dermal filler products. Revance has immediate and exclusive rights to commercialize Teoxane’s Resilient Hyaluronic Acid® (R
- Alastin Skincare Receives Third Patenthttps://modernaesthetics.com/news/elastin-skincare-receives-third-patent/2472853/Alastin Skincare, Inc. has received a third US Patent from the United States Patent and Trademark Office. The patent covers Alastin’s innovative science and products. US Patent No. 10,493,011 is entitled, "Peptide Compositions and Methods for Ameliorating Skin Laxity and Bod
- It's A Deal: Baring Private Equity Asia Agrees to Acquire Lumenishttps://modernaesthetics.com/news/its-a-deal-baring-private-equity-asia-agrees-to-acquire-lumenis/2472848/Baring Private Equity Asia’s affiliated private equity funds are acquiring Lumenis. The transaction, which values Lumenis at an enterprise value of more than $1 billion, remains subject to the customary regulatory approval process. It is expected to be completed in early 2020. <
- Kylie Jenner Sells Majority Stake in Beauty Business to Cotyhttps://modernaesthetics.com/news/kylie-jenner-sells-majority-stake-in-beauty-business-to-coty/2472846/Kylie Jenner sold a $600M majority stake in Kylie Cosmetics and Kylie Skin to Coty Inc. Under the terms of the agreement, Coty will acquire a 51 percent ownership in the partnership for $600M. The acquisition is expected to close in the third quarter of fiscal year 2020. Coty's
- British Plastic Surgeons to Vote on Brazilian Butt Lift Banhttps://modernaesthetics.com/news/british-plastic-surgeons-to-vote-on-brazilian-butt-lift-ban/2472830/It’s been called the deadliest cosmetic surgery procedure in the world, and now the British Association of Aesthetic Plastic Surgeons (BAAPS) is launching a formal safety review of Brazilian butt lifts that will culminate with a vote on whether to ban fat grafting buttock augmentation.
- Results of Phase 2 Study Demonstrate Safety and Efficacy of Galderma's Proprietary Liquid Toxinhttps://modernaesthetics.com/news/results-of-phase-2-study-demonstrate-safety-and-efficacy-of-galdermas-proprietary-liquid/2472827/Results of a Phase 2 study show Galderma’s novel liquid abotulinum toxin, QM1114, is safe and effective for the treatment of glabellar lines. Galderma is now poised to advance to Phase 3 testing of the liquid formulation of botulinum toxin type A for the treatment of glabellar lines. The tr
- FDA Approves Juvéderm Voluma XC For Mid-Face Injection Via Cannulahttps://modernaesthetics.com/news/fda-approves-juvderm-voluma-xc-for-mid-face-injection-via-cannula/2471976/Allergan’s Juvéderm Voluma XC is now U.S. Food and Drug Administration (FDA)-approved for cheek augmentation in the mid-face in adults over 21 with a TSK Steriglide cannula. This cannula features a patented tip design with a near-tip delivery port for precise product p
- Soliton RAP Update: First Patients Treated in Cellulite Trialhttps://modernaesthetics.com/news/soliton-rap-update-first-patients-treated-in-cellulite-trial/2471872/The first patients in Soliton’s cellulite trial have been treated, the Company reports. "Patient treatments have now begun at the Chicago site,” says Dr. Chris Capelli, President, CEO and co-founder of